Duricef

Tonsillitis, Urinary Tract Infections, Bacterial Infections + 3 more
Treatment
8 FDA approvals
15 Active Studies for Duricef

What is Duricef

CefadroxilThe Generic name of this drug
Treatment SummaryCephalexin derivative is an antibiotic that acts for a long time and can treat a wide range of infections. It is also water-soluble.
Duricefis the brand name
image of different drug pills on a surface
Duricef Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Duricef
Cefadroxil
1978
98

Approved as Treatment by the FDA

Cefadroxil, also known as Duricef, is approved by the FDA for 8 uses which include Tonsillitis and Bacterial Infections .
Tonsillitis
Bacterial Infections
Streptococcal Pharyngitis
Skin and Subcutaneous Tissue Bacterial Infections
Urinary Tract Infection (UTI)
Urinary Tract Infections
Tonsillitis streptococcal
Bacterial Infections

Effectiveness

How Duricef Affects PatientsCefadroxil is a type of antibiotic used to treat infections of the urinary tract, skin, throat, and tonsils.
How Duricef works in the bodyCefadroxil works by binding to special proteins in bacteria cells, stopping the bacteria from forming a cell wall. This makes the bacteria vulnerable to being destroyed by its own enzymes, which break down the cell wall and cause the bacteria to die.

When to interrupt dosage

Condition
Dosage
Administration
Urinary Tract Infection (UTI)
, 500.0 mg, 1000.0 mg, 250.0 mg/mL, 500.0 mg/mL, 125.0 mg/mL
, Oral, Capsule, Capsule - Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral
Tonsillitis
, 500.0 mg, 1000.0 mg, 250.0 mg/mL, 500.0 mg/mL, 125.0 mg/mL
, Oral, Capsule, Capsule - Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral
Urinary Tract Infections
, 500.0 mg, 1000.0 mg, 250.0 mg/mL, 500.0 mg/mL, 125.0 mg/mL
, Oral, Capsule, Capsule - Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral
Bacterial Infections
, 500.0 mg, 1000.0 mg, 250.0 mg/mL, 500.0 mg/mL, 125.0 mg/mL
, Oral, Capsule, Capsule - Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral
Streptococcal Pharyngitis
, 500.0 mg, 1000.0 mg, 250.0 mg/mL, 500.0 mg/mL, 125.0 mg/mL
, Oral, Capsule, Capsule - Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral
Communicable Diseases
, 500.0 mg, 1000.0 mg, 250.0 mg/mL, 500.0 mg/mL, 125.0 mg/mL
, Oral, Capsule, Capsule - Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral

Warnings

Duricef Contraindications
Condition
Risk Level
Notes
Pulse Frequency
Do Not Combine
There are 20 known major drug interactions with Duricef.
Common Duricef Drug Interactions
Drug Name
Risk Level
Description
Neomycin
Major
The risk or severity of nephrotoxicity can be increased when Cefadroxil is combined with Neomycin.
Tenofovir
Major
Cefadroxil may increase the nephrotoxic activities of Tenofovir.
Tenofovir alafenamide
Major
Cefadroxil may increase the nephrotoxic activities of Tenofovir alafenamide.
Tenofovir disoproxil
Major
Cefadroxil may increase the nephrotoxic activities of Tenofovir disoproxil.
Vibrio cholerae CVD 103-HgR strain live antigen
Major
The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Cefadroxil.
Duricef Toxicity & Overdose RiskTaking too much of this drug can cause nausea, vomiting, diarrhea, and allergic skin rashes.
image of a doctor in a lab doing drug, clinical research

Duricef Novel Uses: Which Conditions Have a Clinical Trial Featuring Duricef?

39 active investigations are evaluating the potential of Duricef in ameliorating Communicable Diseases, Urinary Tract Infection and Streptococcal Pharyngitis.
Condition
Clinical Trials
Trial Phases
Streptococcal Pharyngitis
0 Actively Recruiting
Communicable Diseases
0 Actively Recruiting
Bacterial Infections
0 Actively Recruiting
Urinary Tract Infections
7 Actively Recruiting
Not Applicable, Phase 4
Urinary Tract Infection (UTI)
6 Actively Recruiting
Phase 1, Phase 3, Phase 4, Phase 2
Tonsillitis
0 Actively Recruiting

Duricef Reviews: What are patients saying about Duricef?

5Patient Review
7/16/2013
Duricef for Urinary Tract Infection
I've had to deal with several UTIs in my life and, thankfully, Duricef has always been there for me. It's completely cleared every infection I've had within a week and I haven't experienced any side effects whatsoever.
5Patient Review
10/7/2011
Duricef for Infection of the Urinary Tract caused by Proteus Bacteria
I had strep throat and a urinary tract infection at the same time. This medication cleared up both infections within two days.
3.3Patient Review
5/31/2009
Duricef for Strep Throat
I developed a rash one day after finishing the treatment.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about duricef

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Duricef a penicillin?

"How does cefadroxil work? Cefadroxil works by preventing bacteria from making their own protective covering. This makes it easier for the body's immune system to kill the bacteria.

Is cefadroxil a penicillin? No, cefadroxil is not a penicillin. It is a cephalosporin antibiotic."

Answered by AI

Is Duricef the same as Keflex?

"Keflex is used to treat bacterial infections, and is available as a generic. Duricef is also available as a generic. Both drugs are available in different forms (tablet, capsule, and suspension), and are used to treat many types of bacterial infections."

Answered by AI

What is the drug Duricef used for?

"It will not work for virus infections (such as common cold, flu).

This medication is for treating bacterial infections. It is in a class of drugs called cephalosporin antibiotics. The medication works by stopping the growth of bacteria. This antibiotic can only treat bacterial infections and not virus infections."

Answered by AI

Clinical Trials for Duricef

Image of UPMC Magee-Womens Hospital in Pittsburgh, United States.

Catheterization Methods for Postpartum Urinary Problems

18+
All Sexes
Pittsburgh, PA
At least ten percent of patients have postpartum urinary retention or difficulty urinating after birth, which can cause incontinence and other urinary problems long-term. After getting an epidural placed, patients should be numb in their pelvic region. This numbness makes it difficult to feel the need to urinate, so patients need a urinary catheter placed to empty the bladder. Some patients have one catheter placed throughout their labor and others have a catheter placed to empty the bladder then removed every few hours. The investigators are studying whether placing a catheter once or catheterizing multiple times affects the rate of postpartum urinary problems and infection.
Waitlist Available
Has No Placebo
UPMC Magee-Womens HospitalAnna Binstock, MD
Image of University of California, San Francisco in San Francisco, United States.

Trimethoprim-Sulfamethoxazole for Urinary Tract Infections

13 - 29
All Sexes
San Francisco, CA
The goal of this clinical trial is to learn if a common antibiotic called trimethoprim-sulfamethoxazole (TMP-SMX) can help prevent urinary tract infections (UTIs) in children and young adults who recently had a kidney transplant. Most people take TMP-SMX for about 6 months after getting a kidney transplant. In this study, researchers want to see what happens if people keep taking it for 6 more months. The main questions this study is asking are: * Does TMP-SMX lower the number of UTIs in the first year after transplant? * What side effects or problems do participants have while taking TMP-SMX? Researchers will compare TMP-SMX to a placebo (a look-alike pill that does not contain any medication) to see if TMP-SMX works to prevent UTIs. Participants will: * Take either TMP-SMX or a placebo pill by mouth every day for 6 months * Have three visits to touch base with the study team about any issues * Complete short monthly online surveys about any symptoms or side effects * Share blood and urine test results from their regular transplant clinic visits
Phase 4
Waitlist Available
University of California, San FranciscoAlexandra Bicki, MD
Have you considered Duricef clinical trials? We made a collection of clinical trials featuring Duricef, we think they might fit your search criteria.Go to Trials
Image of Atlantic Health in Morristown, United States.

Methenamine for Urinary Tract Infection

18 - 100
Female
Morristown, NJ
Stress urinary incontinence (SUI) affects at least 40% of women in the United States. Synthetic polypropylene mid-urethral slings (MUS) are the gold standard treatment for SUI. Post-operative urinary tract infections (UTI) are one of the most common complications after MUS placement. Some studies have demonstrated that MUS placement can increase the risk of UTI up to 21-34%. Post-operative UTI can lead to significant healthcare and patient burden. This additional burden further contributes to an estimated annual cost of $1.6 billion for UTI management in the United States. With increased antibiotic usage, there is simultaneous increase in bacterial resistance leading to treatment refractory UTI. The investigators prescribe post-operative antibiotics prophylactically for 3 days after MUS placement with or without concurrent pelvic reconstructive surgery based on prior literature recommending post-operative prophylaxis. There is a greater emphasis on limiting antibiotic use given the trend of development of bacterial resistance. There are studies supporting alternatives such as methenamine for recurrent UTI prophylaxis treatment, but there are limited studies evaluating methenamine for UTI prophylaxis after MUS.
Recruiting
Has No Placebo
Atlantic Health
Image of Harbor UCLA Medical Center - Medicine - Infectious Diseases in Torrance, United States.

Optimized Beta-lactam Dosing for Bacterial Infections

18+
All Sexes
Torrance, CA
The purpose of this study is to evaluate the abilities of Cystatin C (CysC) and CysC-based estimated Glomerular Filtration Rate (eGFR) equations to characterize the pharmacokinetics (PK) profiles of meropenem and cefepime relative to Serum Creatinine (SCR), Serum Creatinine based Equation (SCRE)and iohexol at the population and individual levels in critically ill adult patients with suspected or documented AMR Gram-negative infections. We hypothesize that CysC and CysC-based eGFR equations will characterize the PK profiles of meropenem and cefepime at the population and individual levels with greater accuracy and precision than SCR and SCREs. Iohexol will be administered to patients enrolled in the study and serve as the reference indicator of measured Glomerular Filtration Rate (mGFR), which is the gold standard assessment of kidney function. We hypothesize that the predictive performances of CysC and CysC-based eGFR equations in estimating the PK profiles of meropenem and cefepime at the population and individual levels will be comparable to iohexol. The information obtained in this study will be used to develop PK/pharmacodynamics (PD) optimized meropenem and cefepime dosing schemes based on the renal function biomarker population PK (PopPK) model with the best predictive performance for clinical use in the treatment of critically ill adult patients with suspected or documented AMR Gram-negative infections and varying degrees of renal function. The primary objective of this study is to compare the abilities of renal function biomarkers (CysC, CysC-based eGFR equations, SCR, SCREs) relative to iohexol to characterize the PK profiles of meropenem and cefepime in critically ill adult patients with suspected or documented AMR Gram-negative infections.
Phase 4
Recruiting
Harbor UCLA Medical Center - Medicine - Infectious Diseases (+9 Sites)
Have you considered Duricef clinical trials? We made a collection of clinical trials featuring Duricef, we think they might fit your search criteria.Go to Trials
Image of Vriginia Mason Medical Center in Seattle, United States.

Antibiotic Usage for Overactive Bladder

18+
All Sexes
Seattle, WA
Intradetrusor injection of onabotulinumtoxinA, which is performed through a cystoscopic procedure, has been demonstrated to be efficacious in the treatment of both neurogenic and non-neurogenic overactive bladder (OAB), and is FDA approved as a treatment for overactive bladder. Intradetrusor of onabotulinumtoxinA is currently standard of care of patients with OAB who have persistent OAB symptoms despite behavioral therapies and oral medication treatments for OAB. As one of the main adverse events associated with intradetrusor injection of onabotulinumtoxinA is UTI, and published guidelines for cystoscopic procedures with manipulation recommend the use of prophylactic antibiotics, a single dose of prophylactic antibiotic is administered prior to this procedure. However, these recommendations are primarily based on data from randomized controlled trials (RCTs) involving antimicrobial prophylaxis during transurethral resection of the prostate. A previously published prospective study demonstrated that the rate of post-procedural UTI did not differ amongst patients with neurogenic bladder who did not receive prophylactic antibiotics and were asymptomatic for UTI, regardless of whether they had sterile urine cultures or asymptomatic bacteriuria, suggesting that patients who are not symptomatic for UTI may not require antibiotic prophylaxis prior to intradetrusor onabotulinumtoxinA injection. Studies have reported that up to 50% of antibiotic usage is inappropriate, leading to unnecessary exposure of patients to potential complications of antibiotic therapy, including Clostridium difficile infection which can cause recurrent diarrhea that may progress to sepsis and death, increasing antibiotic resistances, as well as dermal/allergic and gastro-intestinal manifestations. Therefore, in an effort to optimize antibiotic use, the investigators propose a prospective, randomized study to formally evaluate the differences in UTI frequency in subjects who have a negative urinalysis and are not symptomatic for UTI and receive prophylactic antibiotics at the time of intradetrusor onabotulinumtoxinA injection compared to those who do not receive prophylactic antibiotics at the time of injection. The proposed study seeks to evaluate the current practice standard of antibiotic prophylaxis prior to intradetrusor onabotulinumtoxin injection.
Recruiting
Has No Placebo
Vriginia Mason Medical Center (+1 Sites)Justina Tam, MD
Image of Hospital of the University of Pennsylvania in Philadelphia, United States.

11C-Trimethoprim Imaging for Bacterial Infection

18+
All Sexes
Philadelphia, PA
Patients with suspected bacterial infection at the time screening are eligible for this study. Patients may participate in this study if they are at least 18 years of age, and most participants will be receiving care at the clinical practices of the University of Pennsylvania. Up to 30 subjects will participate in two different imaging cohorts. The Biodistribution cohort will include up to 5 patients referred from orthopedics who will undergo a series of vertex to mid-thigh (or feet if indicated) biodistribution \[11C\]trimethoprim PET/CT scans over a period of approximately 2 ½ hours. The Dynamic cohort will include up to 25 patients who will undergo approximately 60 minutes of dynamic scanning followed by up to 2 static skull base to mid-thigh (or feet if indicated) scans imaging post injection of \[11C\]trimethoprim. Some subjects who may be selected clinically to undergo surgical or antibiotic treatment may undergo a second therapy may also undergo an optional second \[11C\]trimethoprim PET/CT after the initiation of therapy to collect pilot data on the changes in \[11C\]trimethoprim biodistribution and uptake with therapy, the timing of this scan may vary depending on the type of treatment the patient is receiving. Patients will also undergo baseline lab tests complete blood count (CBC), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) and blood cultures. If these tests are done as part of clinical standard of care they will not need to be repeated for this study.
Phase 1
Waitlist Available
Hospital of the University of PennsylvaniaDavid Mankoff, MD PhD
Have you considered Duricef clinical trials? We made a collection of clinical trials featuring Duricef, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security